Urethra neoplasm

Summary

Urethra neoplasm (MONDO:0021239) is a cancer and 7 clinical trials. Top therapeutic interventions include cabozantinib, crizotinib, and enfortumab vedotin. A subtype of urethral disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	urethra neoplasm
Mondo ID	MONDO:0021239
EFO	EFO:0003846
NCIT	C3428
UMLS	C0041971
MedGen	12014
Anatomy (UBERON)	UBERON:0000057
Is cancer (heuristic)	yes

Also known as: neoplasm of the urethra · neoplasm of urethra · neoplasms. urethra · tumor of the urethra · tumor of urethra · tumors. urethra · tumour of the urethra · tumour of urethra · urethra neoplasm (disease) · urethra neoplasms · urethra tumor · urethra tumors · urethra tumour · urethra tumours · urethral neoplasm · urethral neoplasms · urethral tumor · urethral tumors · urethral tumour · urethral tumours

Disease family

This is a subtype of urethral disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urethral disorder › urethra neoplasm

Related subtypes (9): prolapse of urethra, urethral obstruction, urethral intrinsic sphincter deficiency, urethral syndrome, urethral false passage, urethral calculus, urethral gland abscess, urethritis, fibroepithelial polyp of urethra

Subtypes (3): urethral villous adenoma, benign urethral neoplasm, urethra cancer

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Carboplatin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Gemcitabine.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	5
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06638931	PHASE2	RECRUITING	Agnostic Therapy in Rare Solid Tumors
NCT00077688	PHASE2	COMPLETED	TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
NCT01688999	PHASE2	COMPLETED	Cabozantinib for Advanced Urothelial Cancer
NCT02612194	PHASE2	TERMINATED	LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
NCT03219333	PHASE2	COMPLETED	A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
NCT03288545	PHASE1/PHASE2	TERMINATED	A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
NCT01352962	PHASE1	COMPLETED	Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	1
CRIZOTINIB	4	1
ENFORTUMAB VEDOTIN	4	1
PACLITAXEL	4	1
CHEMBL4215501	0	1
CHEMBL4849721	0	1
CHEMBL1825138	0	1
CHEMBL1825141	0	1
EXELIXIS	0	1